Towards new therapeutic strategies in chondrosarcoma Schrage, Y.M.

Citation

Schrage, Y. M. (2009, November 5). Towards new therapeutic strategies in chondrosarcoma. Retrieved from https://hdl.handle.net/1887/14327

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/14327

Note: To cite this publication please use the final published version (if applicable).

reveals Src-pathway activity and dasatinib as option for treatment

Yvonne M. Schrage, Inge H. Briaire-de Bruijn, Noel F. de Miranda, Jolieke van Oosterwijk, Antonie H.M. Taminiau, Tom van Wezel, Pancras C.W. Hogendoorn, Judith V.M.G.Bovée.

Cancer Res 2009; 69:6216-22



Abstract

Chondrosarcomas are notorious for their resistance to conventional chemo- DQG UDGLRWKHUDS\ LQGLFDWLQJ WKHUH DUH QR FXUDWLYH WUHDWPHQW SRVVLELOLWLHV

IRUSDWLHQWVZLWKLQRSHUDEOHRUPHWDVWDWLFGLVHDVH:HWKHUHIRUHH[SORUHGWKH

H[LVWHQFH RI PROHFXODU WDUJHWV IRU V\VWHPLF WUHDWPHQW RI FKRQGURVDUFRPD

XVLQJNLQRPHSURÀOLQJ3HSWLGHDUUD\ZDVSHUIRUPHGIRUFKRQGURVDUFRPDFHOO

OLQHVDQGSULPDU\FKRQGURVDUFRPDFXOWXUHVZLWK*,67PHVHQFK\PDO

VWHPFHOOVDQGFRORUHFWDOFDQFHUFHOOOLQHVDVFRQWUROV$FWLYLW\RINLQDVHV

ZDV YHULÀHG XVLQJ LPPXQREORW DQG DFWLYH 6UF DQG 3'*)5 VLJQDOOLQJ

ZHUHIXUWKHUH[SORUHGXVLQJLPDWLQLEDQGGDVDWLQLERQFKRQGURVDUFRPDin vitro7KH$.7*6.%SDWKZD\ZDVFOHDUO\DFWLYHLQFKRQGURVDUFRPD,Q

DGGLWLRQWKH3'*)5SDWKZD\DQGWKH6UFNLQDVHIDPLO\ZHUHDFWLYH3'*)5

DQG 6UF NLQDVHV FDQ EH LQKLELWHG E\ LPDWLQLE DQG GDVDWLQLE UHVSHFWLYHO\

:KLOH LPDWLQLE GLG QRW VKRZ DQ\ HIIHFW RQ FKRQGURVDUFRPD FHOO FXOWXUHV

GDVDWLQLEVKRZHGDGHFUHDVHLQFHOOYLDELOLW\DWQDQRPRODUFRQFHQWUDWLRQVLQ

RXWRIFKRQGURVDUFRPDFXOWXUHV+RZHYHULQKLELWLRQRISKRVSKRU\ODWHG

6UF < ZDV IRXQG ERWK LQ UHVSRQVLYH DQG QRQUHVSRQVLYH FHOOV ,Q

FRQFOXVLRQXVLQJNLQRPHSURÀOLQJZHIRXQGWKH6UFSDWKZD\WREHDFWLYH

LQFKRQGURVDUFRPD0RUHRYHUZHVKRZHGin vitroWKDWWKHLQKLELWRURIWKH

6UF SDWKZD\ GDVDWLQLE PD\ SURYLGH D SRWHQWLDO WKHUDSHXWLF EHQHÀW IRU

FKRQGURVDUFRPDSDWLHQWVZKLFKDUHQRWHOLJLEOHIRUVXUJHU\

Introduction

&XUDWLYH WUHDWPHQW RI FKRQGURVDUFRPD RI ERQH LV UHVWULFWHG WR VXUJHU\

VLQFH WKLV WXPRXU LV UHSRUWHG WR EH H[WUHPHO\ FKHPR DQG UDGLRWKHUDS\

resistant against conventional therapeutic modalities^. Therefore, there is not much to offer with curative intent to patients with metastatic disease RUZLWKWXPRXUVDWLQRSHUDEOHVLWHV:KHUHDVORZJUDGHFKRQGURVDUFRPDV

JUDGH , DUH WUHDWHG E\ PDUJLQDO RU LQWUDOHDVLRQDO H[FLVLRQ IROORZHG E\

PDUJLQ LPSURYHPHQW E\ DSSOLFDWLRQ RI IHQRO RU FU\RVXUJHU\^, high-grade FKRQGURVDUFRPDLVWUHDWHGE\RIWHQPXWLODWLQJODUJHHQEORFUHVHFWLRQRU

DPSXWDWLRQ 7KH PHWDVWDWLF UDWH RI FKRQGURVDUFRPD LV GLUHFWO\ UHODWHG WR

histological grade⁵ FXUUHQWO\ EHLQJ WKH RQO\ SUHGLFWRU RI RXWFRPH ZKLOH

KLVWRORJLFDOJUDGHLVKLJKO\VXEMHFWHGWRLQWHUREVHUYHUYDULDELOLW\^. Grade I FKRQGURVDUFRPDVDOPRVWQHYHUPHWDVWDVL]HZKLOHPHWDVWDVHVRFFXULQ

RIJUDGH,,FKRQGURVDUFRPDVDQGLQRIJUDGH,,,FKRQGURVDUFRPDV^. The

\HDUVXUYLYDOUDWHIRUSDWLHQWVZLWKKLJKJUDGHFKRQGURVDUFRPDLVSRRU

IRUJUDGH,,DQGRQO\IRUJUDGH,,,WXPRXUV

Few recurrent genetic alterations were found in chondrosarcoma, pointing WRZDUGV D ORVV RI FHOO F\FOH FRQWURO RI FKRQGURVDUFRPD VXFK DV JDLQ RI

&'.^ DQG ORVV RI S^ 'HFUHDVHG FHOO YLDELOLW\ ZDV GHPRQVWUDWHG

DIWHUUHVWRUDWLRQRISH[SUHVVLRQRUWKHNQRFNGRZQRI&'.E\VK51$

in chondrosarcoma cells in vitro^. So far there is little evidence for a role IRUNLQDVHLQKLELWRUVLQFKRQGURVDUFRPDWUHDWPHQW,QDGGLWLRQWR&'.^,

$.7^DQG)ON.'53'*)5%^DQG)*)5^ZHUHVKRZQWREHDFWLYDWHG

DQGVXJJHVWHGDVSRVVLEOHWDUJHWVLQWKHWUHDWPHQWRIFKRQGURVDUFRPD

,QWKHSUHVHQWVWXG\ZHH[SORUHGQHZWUHDWPHQWRSWLRQVIRUFKRQGURVDUFRPD

XVLQJNLQRPHSURÀOLQJ.LQDVHVDUHHQ]\PHVWKDWSKRVSKRU\ODWHW\URVLQH

VHULQH RU WKUHRQLQH UHVLGXHV RQ RWKHU SURWHLQV 7KH\ SOD\ D PDMRU UROH

LQ VLJQDOOLQJ FDVFDGHV WKDW GHWHUPLQH FHOO F\FOH HQWU\ FHOO VXUYLYDO DQG

GLIIHUHQWLDWLRQ IDWH ZKLFK DUH RIWHQ GHUHJXODWHG LQ WXPRXUV .LQDVHV DUH

H[FHOOHQW WDUJHWV IRU DQWLFDQFHU WKHUDS\ VLQFH WKH\ ZRUN DV D PROHFXODU

VZLWFKWKHLUUHJXODWLRQLVUHYHUVLEOHUDSLGPHUHO\LQVHFRQGVDQGGRHVQRW

UHTXLUHQHZSURWHLQV\QWKHVLVUHYLHZHGLQ^

.LQRPH SURÀOLQJ DOORZV WKH GHWHFWLRQ RI NLQDVH DFWLYLW\ LQ FHOO O\VDWHV

E\ GHWHFWLQJ WKH OHYHO RI VXEVWUDWH SKRVSKRU\ODWLRQ 7KLV SURGXFHV D

comprehensive description of cellular signal transduction in a particular VDPSOHZKLFKFDQEHDVVLJQHGWRVSHFLÀFSDWKZD\VDVKDVEHHQVKRZQE\

Diks et al.^.LQRPHSURÀOLQJLGHQWLÀHGWKH$.7*6.%SDWKZD\3'*)5%

DQGWKH6UFSDWKZD\DVSRWHQWLDOWDUJHWVIRUFKRQGURVDUFRPDWUHDWPHQW

:HVKRZHGWKDWLQKLELWLRQRIWKH6UFSDWKZD\E\GDVDWLQLELQGHHGUHVXOWHG

LQGHFUHDVHGFHOOYLDELOLW\LQRXWRIFKRQGURVDUFRPDFHOOFXOWXUHVin vitro.

90

Material and methods Reagents

,PDWLQLE PHV\ODWH *OLYHF*OHHYHF 67, ZDV REWDLQHG IURP 1RYDUWLV

%DVHO 6ZLW]HUODQG DQG GDVDWLQLE 6SU\FHO %06  IURP %ULVWRO

0\HUV6TXLEE1HZ<RUN86$%RWKGUXJVZHUHGLVVROYHGLQ'062

Cell culture

&KRQGURVDUFRPDFHOOOLQHVFKRQGURVDUFRPDSULPDU\FXOWXUHV7DEOHDQG

DJDVWURLQWHVWLQDOVWURPDOWXPRXUFHOOOLQH*,67^ZHUHFXOWXUHGLQ530,

*LEFR,QYLWURJHQ/LIH7HFKQRORJLHV6FRWODQG8.VXSSOHPHQWHGZLWK

KHDWLQDFWLYDWHGIRHWDOFDOIVHUXP*LEFR*,67DJDVWURLQWHVWLQDO

VWURPDOWXPRXUFHOOOLQHFDUU\LQJDKRPR]\JRXVH[RQPLVVHQVHPXWDWLRQ

.(LQ.,7^DQGNQRZQWREHLPDWLQLEVHQVLWLYHZDVXVHGWUHDWHGDQG

untreated, as a proof of principle of the Pepchip^® technique. Two cell cultures RIQRUPDOERQHPDUURZGHULYHGPHVHQFK\PDOVWHPFHOOV06&V/DQG

/ ZHUH XVHG DV QRQQHRSODVWLF FRXQWHUSDUW FRQWURO ,Q DGGLWLRQ DQ

LQGHSHQGHQWVHWRIFRORUHFWDOFDUFLQRPDFHOOOLQHVZHUHWHVWHG+75.2

/66:6:WRHVWLPDWHVSHFLÀFLW\

&HOOVZHUHJURZQDWž&LQDKXPLGLÀHGLQFXEDWRUZLWKDLUDQG

CO₂ 7KH FDUWLODJLQRXV SKHQRW\SH RI WKH FKRQGURVDUFRPD FXOWXUHV ZDV

FRQÀUPHGE\573&5VKRZLQJP51$H[SUHVVLRQRIFROODJHQV,%DQG

$JJUHFDQDQG62;^.

Sample Type Grade Gender Age Passage

 2806³⁹ Cell line III m na 

2 &+^ Cell line III f 35 

3 6: Cell line II f 72 53

 &^ Cell line II m  

5 / 3ULPDU\FXOWXUH II m  

 / 3ULPDU\FXOWXUH I f 53 

7 / 3ULPDU\FXOWXUH III m 55 

 / 3ULPDU\FXOWXUH II m 52 27

9 / 3ULPDU\FXOWXUH II f  

 / 3ULPDU\FXOWXUH III f  

 L2252 3ULPDU\FXOWXUH I f 29 7

 L2279 3ULPDU\FXOWXUH I f  7

 / 3ULPDU\FXOWXUH II m  

Table 5.1 Chondrosarcoma cultures. naQRWDYDLODEOH 6:ZDVREWDLQHG

IURP$PHULFDQ7\SH&XOWXUH&ROOHFWLRQ0DQDVVDV9$86$

Kinome array analysis

$NLQDVHVXEVWUDWHSHSWLGHDUUD\ZDVXVHGFRQWDLQLQJGLIIHUHQWNLQDVH

VXEVWUDWHVVSRWWHGLQWULSOLFDWHZLWKQHJDWLYHDQGSRVLWLYHFRQWUROV

3HSFKLS.LQRPLFV3HSVFDQ3UHVWR/HO\VWDGWKH1HWKHUODQGV&HOOVZHUH

KDUYHVWHGGXULQJWKHLUH[SRQHQWLDOJURZWKSKDVH&HOOVZHUHZDVKHGWLPHV

ZLWKFROG3%6&HOOO\VLVEXIIHU&HOO6LJQDOOLQJ7HFKQRORJ\&DPEULGJH0$

86$ VXSSOHPHQWHG ZLWK P0 306) ZDV XVHG /\VDWHV ZHUH SURFHVVHG

WKURXJK D 4,$VKUHGGHU 4LDJHQ *HUPDQWRZQ 0' 86$ IRU  PLQXWHV

DQGDÀOWHU0LOOLSRUH%LOOHULFD0$86$IRUPLQXWHVERWKDWƒ&WRUHWDLQ

RSWLPDONLQDVHDFWLYLW\)RUFRQFHQWUDWLRQRIWKHO\VDWHVDQGGLVFDUGLQJRI

WKHO\VLVEXIIHUDN'VSLQFROXPQ0LOOLSRUHZDVXVHGIRUPLQXWHV

DW ƒ& &RQFHQWUDWLRQ RI WKH SURWHLQ O\VDWH ZDV PHDVXUHG XVLQJ WKH DC 3URWHLQ$VVD\%LRUDG+HUFXOHV&$86$)RUNLQDVHDUUD\DQDO\VLVǍJ

RI WKH SURWHLQ ZDV GLOXWHG LQ NLQDVH EXIIHU &HOO 6LJQDOOLQJ 7HFKQRORJ\ LQ WKH SUHVHQFH RI FRPSOHWH PLQL ('7$ IUHH 5RFKH %DVHO 6ZLW]HUODQG DQG  P0 306) 7R ǍO RI WKH O\VDWH ǍO DFWLYDWLRQ PL[ 7ULV+&O

S+ P0 0J&O P0 *O\FHURO  %ULM  %6$ PJ

PO $73 Ǎ0 DQG >DŽ³³3@$73 Ǎ&L ZDV DGGHG $ [ PP FRYHU VOLS

ZDVXVHG7KHVOLGHVZHUHLQFXEDWHGLQDKXPLGFKDPEHUIRUKRXUVDW

ƒ&6XEVHTXHQWO\VOLGHVZHUHULQVHGLQ3%67ULWRQ;WZLFHWKHQ

ZDVKHGWZLFHLQ1D&O07ULWRQ;IRUPLQXWHVIROORZHGE\

ZDVKLQJLQGLVWLOOHGZDWHU$OOEXIIHUVZHUHXVHGDWƒ&DQGZDVKLQJZDV

SHUIRUPHGLQDURWDWLRQVWRYHDWƒ&6XEVHTXHQWO\WKHVOLGHVZHUHGULHG

LQDPOWXEHLQDFHQWULIXJHDWUSP7KHPHDVXUHPHQWRIWKH³³P VLJQDOZDVSHUIRUPHGXVLQJD%LRPROH[UHDGHUIRUUHDOWLPHGLJLWDOLPDJLQJ

RIUDGLRLVRWRSHV%LRPROH[2VOR1RUZD\$WOHDVW[^ hits were collected.

Data analysis

%LRPROH[ 5HDGEDFN 9 DQG %LRVSOLW VRIWZDUH %LRPROH[ ZHUH XVHG

to create a list with intensities using a grid. For further data mining 5SDFNDJHV $II\LR DQG /LPPD ZHUH XVHG KWWSZZZELRFRQGXFWRURUJ

4XDOLW\ RI WKH WULSOLFDWHV DQG GLVWULEXWLRQ RI WKH GDWD ZDV DVVHVVHG DQG

TXDQWLOHQRUPDOLVDWLRQ$II\LRZDVSHUIRUPHG3KRVSKRU\ODWHGVXEVWUDWHV

LQ FKRQGURVDUFRPD FXOWXUHV ZHUH FRPSDUHG ZLWK WKRVH LQ 06&V XVLQJ

Limma which provides functions to summarise results using a linear model WRSHUIRUPK\SRWKHVLVWHVWVDQGDGMXVWWKHSYDOXHVIRUPXOWLSOHWHVWLQJ²⁰. ,QDGGLWLRQWKHGDWDVHWRIFKRQGURVDUFRPDFHOOFXOWXUHVZDVFRPSDUHG

with an independent set of 5 colorectal carcinoma cell lines using Limma.

6XEVHTXHQWO\SKRVSKRU\ODWLRQVLJQDOVRIDOOFKRQGURVDUFRPDFXOWXUHVZHUH

DYHUDJHGDQGWKHWRSWKHFRPPRQGHQRPLQDWRUVZHUHLPSRUWHGIRUFRUH

DQDO\VLVLQ,QJHQXLW\3DWKZD\$QDO\VLVKWWSZZZLQJHQXLW\FRP,3$LV

D OLWHUDWXUH EDVHG SURJUDP WKDW FDOFXODWHV WKH SUREDELOLW\ RI LQYROYHPHQW

RILGHQWLÀHUVLQWKLVFDVHFRPELQDWLRQVRINLQDVHVLQNQRZQFDQRQLFDO

92

Immunoblotting

PJRIHDFKVDPSOHVWRUHGLQNLQDVHEXIIHUDWƒ&ZDVUXQRQ6'6

3$*(3URWHLQVZHUHWUDQVIHUUHGRQWRSRO\YLQ\OLGHQHGLÁXRULGHPHPEUDQHV

,PPRELORQ3 0LOOLSRUH XVLQJ HOHFWURSKRUHVLV 0HPEUDQHV ZHUH SUH

LQFXEDWHGZLWKVNLQQHGPLONLQSKRVSKDWHEXIIHUHGVDOLQH7ZHHQ

$IWHU LQFXEDWLRQ ZLWK ÀUVW DQG VHFRQGDU\ DQWLERGLHV WKH PHPEUDQHV

ZHUHGHYHORSHGZLWK(&/⁷⁰:HVWHUQEORWWLQJGHWHFWLRQUHDJHQW$PHUVKDP

Biosciences, %XFNLQJKDPVKLUH 8. DQG YLVXDOLVHG E\ H[SRVXUH WR ;UD\

ÀOPV+\SHUÀOP(&/$PHUVKDP%LRVFLHQFHV%XFNLQJKDPVLUH8..

5DEELW PRQRFORQDO DQWLERGLHV DJDLQVW SKRVSKRF5DI 6HU $

SKRVSKR0(. 6HU * SKRVSKRS 0$3.

(UN 7KU7\U '( SKRVSKRS56. 6HU ' SKRVSKRU\ODWHG $.7 6HU '( SKRVSKRU\ODWHG $.7 7KU &(SDQ$.7&(*6.%&DQGUDEELWDQWLERGLHVDJDLQVW

SKRVSKRU\ODWHG F5DI 6HU DQG SKRVSKRU\ODWHG *6.% 6HU ZHUH

REWDLQHG IURP &HOO VLJQDOOLQJ 7HFKQRORJ\ Jurkat cells, treated with /<RU&DO\FXOLQ$ZHUHXVHGDVDQHJDWLYHDQGSRVWLYHFRQWUROIRU$.7

SKRVSKRU\ODWLRQ UHVSHFWLYHO\ 3RO\FORQDO DQWLERG\ WR SKRVSKRU\ODWHG 6UF

<ZDVREWDLQHGIURP5 '6\VWHPV0LQQHDSROLV0186$0RQRFORQDO

DQWLERG\WRWRWDO6UFFORQH*'ZDVREWDLQHGIURP8SVWDWH%LRWHFKQRORJ\

/DNH3ODFLG1<86$3URFDVSDVHN'DDQGEHWDWXEXOLQDQWLERGLHV

ZHUHIURP&HOO6LJQDOOLQJ7HFKQRORJ\DQG6LJPD$OGULFK6W/RXLVH02

86$UHVSHFWLYHO\

In vitro proliferation assays

5HVSRQVHRIFKRQGURVDUFRPDSULPDU\FXOWXUHVWRHVFDODWLQJGRVHVRILPDWLQLE

UDQJH²Ǎ0ZDVPHDVXUHGE\FHOOFRXQWXVLQJD%UNHUFKDPEHU

*,67 ZDV XVHG DV SRVLWLYH FRQWURO 5HVSRQVH RI FKRQGURVDUFRPD FHOO

OLQHVDQGSULPDU\FXOWXUHVWRHVFDODWLQJGRVHVGDVDWLQLEUDQJHQ0²

Ǎ0ZDVPHDVXUHGHLWKHUE\WULWLXPLQFRUSRUDWLRQDVVD\2806&+

6: / / RU :67 FRORULPHWULF DVVD\ 5RFKH 'LDJQRVWLFV

*PE+3HQ]EHUJ*HUPDQ\////ZKLFKPHDVXUHV

PLWRFKRQGULDODFWLYLW\DVGHVFULEHGSUHYLRXVO\^&/DQG/GLG

QRW UHDFK DQ DGHTXDWH SUROLIHUDWLRQ UDWH WR DOORZ LQKLELWLRQ H[SHULPHQW

5HVXOWVZHUHFRPSDUHGWRDSRRUUHVSRQGLQJ$//&5DQGDZHOOUHVSRQGLQJ

DFXWHO\PSKREODVWLFOHXNHPLD$//&0FHOOOLQHDQGDVZHOODVWR*,67

NQRZQ WR UHVSRQG WR GDVDWLQLE DW a Q0²² ,Q EULHI  FHOOV ZHUH

VHHGHGLQDZHOOVSODWHDQGZHUHDOORZHGWRLQFXEDWHZLWKWKHGUXJVIRU

72 hours. ³+ZDVDGGHGDQGWKHIROORZLQJGD\FHOOVZHUHKDUYHVWHGXVLQJ

WKH )LOWHU0DWH V\VWHP 3HUNLQ (OPHU :DOWKDP 0$ 86$³+WK\PLGLQH

LQFRUSRUDWLRQZDVPHDVXUHGXVLQJD7RS&RXQWVFLQWLOODWLRQFRXQWHU3HUNLQ

(OPHU$OOH[SHULPHQWVZHUHSHUIRUPHGLQGXSOLFDWHDQGLQWKHSUHVHQFHRI

DPD[LPXPRI'062,QYLWURH[SHULPHQWVZHUHSHUIRUPHGDWOHDVW

WKUHHWLPHV*UDSKVVKRZGDWDIURPRQHUHSUHVHQWDWLYHH[SHULPHQW(UURU

EDUVLQGLFDWHWKHVWDQGDUGHUURURIWKHPHDQ

Results

,GHQWLÀFDWLRQRIDFWLYHNLQDVHVLQFKRQGURVDUFRPDFXOWXUHV

7KURXJKNLQRPHSURÀOLQJRIFKRQGURVDUFRPDFXOWXUHVZHFUHDWHGDOLVWRI

SKRVSKRU\ODWHGWDUJHWVDQGWKHLUFRUUHVSRQGLQJDFWLYHNLQDVHV7KHWRS

RIFKRQGURVDUFRPDWDUJHWVZDVDQDO\VHGXVLQJ,3$UDQNLQJWKHLPSRUWDQFH

RIWKHFRUUHVSRQGLQJNLQDVHVLQFKRQGURVDUFRPDV7KHVSHFLÀFLW\RIWKLVOLVW

RIVXEVWUDWHVIRUFKRQGURVDUFRPDZDVYHULÀHGE\FRPSDULQJWKHLQWHQVLW\RI

WKHVLJQDOVZLWKWKRVHIRUQRUPDO06&VXVLQJ/LPPD6XSSOHPHQWDU\WDEOH

 %DVHG RQ WKH DYHUDJH VSRW LQWHQVLW\ DQG KRZ IUHTXHQW WKHLU WDUJHWV

ZHUH SUHVHQW LQ WKH WRS  RI VXEVWUDWHV  NLQDVHV ZHUH LGHQWLÀHG E\

,3$DQDO\VLV7DEOH7KH$.7SDWKZD\$.7DQG*6.%ZDVIRXQG

WR EH WKH PRVW DFWLYH SDWKZD\ LQ FKRQGURVDUFRPD IROORZHG E\ 7LWLQ DQG

536NLQDVH$OVRWKH6UFSDWKZD\)<1DQG/&.DQGWKH5DV5DI0(.

(5. SDWKZD\ VWLPXODWHG E\ 3'*)5% ZHUH DFWLYH LQ FKRQGURVDUFRPD ,Q

addition, Aurorakinase B and CDC2 were found.

9HULÀFDWLRQRINLQRPHSURÀOLQJ

.LQRPHSURÀOLQJRIXQWUHDWHG*,67UHYHDOHGDQDFWLYH5DV5DI0(.

(5.SDWKZD\ZKLFKLVDFWLYDWHGE\.,76XSSOHPHQWDU\WDEOH*,67

FDUULHV DQ DFWLYDWLQJ .,7 PXWDWLRQ^ 6XEWUDFWLQJ WKH DYHUDJH LQWHQVLWLHV

RIXQWUHDWHG*,67IURPWKHǍ0LPDWLQLEWUHDWHG*,67UHYHDOHG

WKDW LQGHHG WKH 5DV5DI0(.(5. SDWKZD\ ZDV WDUJHWHG E\ LPDWLQLE

ZKLFK ZDV FRQÀUPHG E\ DQDO\VLV XVLQJ ,3$ GDWD QRW VKRZQ ,QKLELWLRQ

RI WKH 5DV5DI0(.(5. SDWKZD\ LQ *,67 E\ LPDWLQLE ZDV YHULÀHG

E\LPPXQREORWXVLQJWKHVDPHO\VDWHVDVK\EULGLVHGRQWKHNLQDVHDUUD\

6WDLQLQJIRUF5DI0(.(5.DQG56.ZDVGHFUHDVHGDIWHUǍ0

LPDWLQLEWUHDWPHQW)LJXUH$FRQÀUPLQJWKDWWKH5DV5DI0(.(5.

SDWKZD\ZDVWDUJHWHGE\LPDWLQLE

,Q DGGLWLRQ FRPSDULVRQ RI WKH VXEVWUDWH SKRVSKRU\ODWLRQ SDWWHUQV RI DOO

VXEVWUDWHVRIFKRQGURVDUFRPDFHOOFXOWXUHVDQGWKHWZR06&FXOWXUHV

6XSSOHPHQWDU\ WDEOH  DQG WKH  FRORUHFWDO FDUFLQRPD FHOO OLQHV

6XSSOHPHQWDU\WDEOHZDVSHUIRUPHGUHYHDOLQJDQGGLIIHUHQWO\

SKRVSKRU\ODWHGVSRWVUHVSHFWLYHO\DGMXVWHGS

3KRVSKRU\ODWLRQRI$.7LQFKRQGURVDUFRPDFHOOFXOWXUHVFRXOGEHYHULÀHG

E\LPPXQREORWDWERWKWKHVHULQHDQGWKHWKUHRQLQHSRVLWLRQLQ

DOO FXOWXUHV )LJXUH  :KHUHDV WRWDO *6.% ZDV SUHVHQW LQ QHDUO\ DOO

VDPSOHVSKRVSKRU\ODWLRQOHYHOVRI*6.%DWVHULQHZHUHLQGHHGYHU\ORZ

LQWKHFKRQGURVDUFRPDFHOOFXOWXUHVFRQÀUPLQJDFWLYH*6.%F5DIZKLFK

OLQNVWKH$.7SDWKZD\ZLWKWKH0(.(5.SDWKZD\ZDVDOVRGHWHFWHGE\

LPPXQREORWLQDOOSULPDU\FXOWXUHV



IntensityKinaseNr hitsDescriptionDrugs $.799DNWPXULQHWK\PRPDYLUDORQFRJHQHKRPRORJ(Q]DVWDXULQ 2*6.%*O\FRJHQV\QWKDVHNLQDVHEHWD(Q]DVWDXULQ 3 TTN Titin 536.$55LERVRPDOSURWHLQ6NLQDVHN'DSRO\SHSWLGH 5 FYN)<1RQFRJHQHUHODWHGWR65&)*5<(6'DVDWLQLE /&./\PSKRF\WHVSHFLÀFSURWHLQW\URVLQHNLQDVH'DVDWLQLE 7 CDC2&HOOGLYLVLRQF\FOH*WR6DQG*WR0Flavopiridol $85.%2 Aurora kinase B$=' 93$.3&'.1$DFWLYDWHGNLQDVH 330.9023,3.2

3KRVSKDWLG\OLQRVLWROSKRVSKDWH SKRVSKDWLG\OLQRVLWRONLQDVHW\SH,,,

&61.$&DVHLQNLQDVHDOSKDSRO\SHSWLGH &$0.'&DOFLXPFDOPRGXOLQGHSHQGHQWSURWHLQNLQDVH,' (3+%(3+UHFHSWRU% 5+2$5DVKRPRORJJHQHIDPLO\PHPEHU$ 0$3.20LWRJHQDFWLYDWHGSURWHLQNLQDVHNLQDVH3' $.$3$NLQDVH35.$DQFKRUSURWHLQ 35.$&$3URWHLQNLQDVHF$03GHSHQGHQWFDWDO\WLFDOSKD &61.$&DVHLQNLQDVHDOSKD &$0.*3

&DOFLXPFDOPRGXOLQGHSHQGHQWSURWHLQNLQDVH &D0NLQDVH,,JDPPD

203'*)5%

3ODWHOHWGHULYHGJURZWKIDFWRUUHFHSWRUEHWD SRO\SHSWLGH 'DVDWLQLE6XQLWLQLE,PDWLQLE 6RUDIHQLE%HFDSOHUPLQ

6'.

6LGHNLFNKRPRORJFHOODGKHVLRQPROHFXOH FKLFNHQ

Table 5.2 Results from the top 100 phosphorylated substrates (not shown), their corresponding kinases and targeted drugs in chondrosarcoma cultures. 1UKLWVKRZPDQ\WLPHVWKHNLQDVHVZHUHSUHVHQWLQWKHWRSVSRWV)RUHDFKNLQDVHRQO\WKHKLJKHVW DYHUDJHH[SUHVVLRQLVVKRZQKHUH

Figure 5.1: Chondrosarcoma cultures are susceptible to dasatinib but not to imatinib.

$7UHDWPHQWRI*,67ZLWKǍ0LPDWLQLEOHDGVWRDGHFUHDVHLQOHYHOVRIF5DISKRV- SKRU\ODWHG0(.(5.DQGS56.YHULI\LQJLQWHUIHUHQFHZLWKWKH5DV5DI0(.(5.

SDWKZD\E\LPDWLQLE%,PDWLQLEWUHDWPHQWGHFUHDVHVFHOOQXPEHUVLQWKHLPDWLQLEUHVSRQVLYH

*,67FHOOOLQH+RZHYHUIRXUFKRQGURVDUFRPDFXOWXUHVGLGQRWUHVSRQGWRLPDWLQLEWUHDW- PHQWXQOHVVWR[LFFRQFHQWUDWLRQVRIDQGǍ0ZHUHXVHG&'DVDWLQLEFDXVHVGHFUHDVHG

FHOOYLDELOLW\LQRIFKRQGURVDUFRPDSULPDU\FHOOFXOWXUHV$GHFUHDVHLQFHOOYLDELOLW\RI

DWQ0DQGDWQ0ZDVREVHUYHGLQ///DQG/3ULPDU\

FXOWXUH/UHVSRQGHGZLWKDGHFUHDVHLQFHOOJURZWKDWQ0WUHDWPHQW'&HOOOLQHV

2806DQG6:VKRZHGDGHFUHDVHLQYLDELOLW\DWQ0GDVDWLQLEZKHUHDVERWKSULPDU\

FXOWXUH/DQGFHOOOLQH&+VKRZHGDUHVSRQVHRQO\DWORZFRQFHQWUDWLRQVDQG

Q0ZKLOHDWKLJKHUFRQFHQWUDWLRQVQRHIIHFWZDVIRXQG(,QSRVWLWLYHFRQWUROV$//&0DQG

*,67DGHFUHDVHLQFHOOYLDELOLW\RIPRUHWKDQZDVREVHUYHGZKLOHDOLPLWHGHIIHFWZDV

IRXQGLQGDVDWLQLEUHVLVWDQWOHXNHPLDFHOOOLQH&5



Figure 5.2 Chondrosarcoma cultures are characterized by AKT phosphorylation. Findings RI NLQRPH SURÀOLQJ E\ 3HSFKLSŠ DQDO\VLV ZHUH YHULÀHG E\ LPPXQREORW $OO FXOWXUHV VKRZHG

SKRVSKRU\ODWLRQ RI $.7 DW VHULQH  DQG WKUHRQLQH  DOWKRXJK OHYHOV RI SDQ $.7 ZHUH

YDULDEOH:KLOHSDQ*6.%ZDVGHWHFWHGLQQHDUO\DOOVDPSOHVSKRVSKRU\ODWLRQDWVHULQH

ZDVDEVHQWFRQÀUPLQJDFWLYH*6.%3KRVSKRU\ODWHG5DIZDVGHWHFWHGLQQHDUO\DOOVDPSOHV

-XUNDWWUHDWHGZLWK/<RU&DO\FXOLQ$VHUYHGDVDQHJDWLYHDQGSRVLWLYHFRQWURORI

$.7SKRVSKRU\ODWLRQUHVSHFWLYHO\

Chondrosarcomas do not respond to imatinib treatment in vitro

,Q WDEOH  WKH FXUUHQWO\ XVHG NLQDVH LQKLELWRUV VSHFLÀF IRU WKH DFWLYH

NLQDVHV LQ FKRQGURVDUFRPD DUH VKRZQ 'DVDWLQLE DQG LPDWLQLE WDUJHWLQJ

WKH6UFNLQDVHIDPLO\DQG.,73'*)5SDWKZD\UHVSHFWLYHO\ZHUHDYDLODEOH

WRXV6HQVLWLYLW\RIFKRQGURVDUFRPDFHOOVWRERWKGUXJVZDVWHVWHG:KHUHDV

*,67VKRZHGDSURIRXQGGHFUHDVHRIFHOOQXPEHUUHODWLYHWRWKH'062

FRQWURODWORZHUGRVDJHVRILPDWLQLEWKHFKRQGURVDUFRPDSULPDU\FXOWXUHV

GLGQRWVKRZDQ\HIIHFWRQO\DWKLJKFRQFHQWUDWLRQVRILPDWLQLESUREDEO\

GXHWRQRQVSHFLÀFWR[LFLW\UDWKHUWKDQRQWDUJHWHIIHFWV)LJXUH% Chondrosarcomas are responsive to dasatinib treatment in vitro

6HYHQ RXW RI  FKRQGURVDUFRPD FHOO FXOWXUHV UHVSRQGHG WR GDVDWLQLE

WUHDWPHQWZLWKDGHFUHDVHLQFHOOJURZWK3ULPDU\FXOWXUHV//

//VKRZHGGHFUHDVHGFHOOYLDELOLW\DWQ0DQG

GHFUHDVHG YLDELOLW\ DW  Q0 RI GDVDWLQLE WUHDWPHQW DV PHDVXUHG E\

either ³+LQFRUSRUDWLRQRU:67DVVD\)LJXUH&7KHVWURQJHVWHIIHFW

ZDVREVHUYHGLQSULPDU\FXOWXUH/ZLWKDUHGXFWLRQLQFHOOYLDELOLW\

FRPSDUHGWRWKH'062FRQWURODWQ0GDVDWLQLE)LJXUH&,QKLELWLRQ

RIFHOOJURZWKRIWKHFKRQGURVDUFRPDFHOOOLQHV6:2806RFFXUUHG

DWQ0)LJXUH',QFRQWUDVWERWKSULPDU\FXOWXUH/)LJXUH& DQGFHOOOLQH&+)LJXUH'GLGQRWVKRZDQ\HIIHFW3RVLWLYHFRQWUROV

$//&0DQG*,67DQGQHJDWLYHFRQWURO$//&5DUHVKRZQLQÀJXUH(

Dasatinib treatment of chondrosarcoma decreased Src-phosphorylation but does not result in caspase-3 mediated apoptosis

7R LQYHVWLJDWH WKH HIIHFW RI GDVDWLQLE RQ 6UF VLJQDOOLQJ *,67 D JRRG

UHVSRQVLYH FKRQGURVDUFRPD FHOO FXOWXUH / DQG D QRQUHVSRQVLYH

FKRQGURVDUFRPD FHOO OLQH &+ ZHUH WUHDWHG ZLWK LQFUHDVLQJ GRVHV RI

GDVDWLQLE IRU  KRXUV :KHUHDV OHYHOV RI WRWDO 6UF GR QRW GHFUHDVH XSRQ

GDVDWLQLE WUHDWPHQW D GHFUHDVH LQ SKRVSKRU\ODWHG 6UF S6UF < ZDV

IRXQGLQ*,67)LJXUH$$WDGRVLVRIQ0GDVDWLQLEWKHS6UF

VWDLQLQJKDVGLVDSSHDUHG$OVRLQ/WKHUHVSRQVLYHFHOOFXOWXUHOHYHOVRI

SKRVSKRU\ODWHG6UFGHFUHDVHJUDGXDOO\DOWKRXJKERWKEDQGVRIWKHVWDLQLQJ

DUHSUHVHQW)LJXUH%6WULNLQJO\LQ&+WKHOHYHORISKRVSKRU\ODWLRQ

RI 6UF GHFUHDVHG XSRQ GDVDWLQLE WUHDWPHQW DV ZHOO )LJXUH & ZKLOH

QR HIIHFW RQ FHOO YLDELOLW\ ZDV IRXQG 6WDLQLQJ IRU SURFDVSDVH   N'D VKRZHGDJUDGXDOGHFUHDVHLQ*,67XSRQGDVDWLQLEWUHDWPHQWVWDUWLQJDW

Q0VXJJHVWLQJSURFDVSDVHFOHDYLQJDQGDFWLYHFDVSDVHPHGLDWHG

DSRSWRVLV)LJXUH$²³&DVSDVHVWDLQLQJVHHPVWRLQFUHDVHVOLJKWO\DW

Q0DQGWKHQGHFUHDVHVIXUWKHUXQWLOQ0DOOWKRXJKWXEXOLQZDVVOLJKWO\

YDULDEOH3URDSRSWRWLFDFWLRQRIGDVDWLQLEKDVEHHQGHVFULEHGSUHYLRXVO\²². +RZHYHUFDVSDVHPHGLDWHGDSRSWRVLVFRXOGQRWEHGHPRQVWUDWHGLQERWK

FKRQGURVDUFRPDFHOOFXOWXUHV)LJXUH%DQG&



Discussion

&KRQGURVDUFRPDV DUH KLJKO\ UHVLVWDQW WR FRQYHQWLRQDO FKHPR DQG

UDGLRWKHUDS\DQGDVDFRQVHTXHQFHWKHUHLVQRFXUDWLYHWUHDWPHQWRSWLRQ

IRU SDWLHQWV ZLWK LQRSHUDEOH RU PHWDVWDWLF GLVHDVH .LQRPH SURÀOLQJ ZDV

XVHGWRVHDUFKIRUGUXJDEOHNLQDVHVLQFKRQGURVDUFRPD

$PDMRUFDYHDWLQODUJHVFDOHSKRVSKRU\ODWLRQVWXGLHVLVWKHSURPLVFXLW\RI

NLQDVHVLQWKHDEVHQFHRIin vivoUHJXODWLRQVLJQDOVZKLFKPD\OHDGWRIDOVH

SRVLWLYHUHVXOWV,GHDOO\E\FRPSDULQJNLQDVHSURÀOHVZLWKDQGZLWKRXWD

FHUWDLQVWLPXOXVIRULQVWDQFHDNLQDVHLQKLELWRUNLQDVHVEHLQJDFWLYDWHGRU

GHDFWLYDWHGXSRQWKHVWLPXOXVFDQEHGHWHFWHGDVZDVSUHYLRXVO\UHSRUWHG^. +RZHYHUVLQFHWKHUHDUHQRFRPSRXQGVDYDLODEOHWKDWDUHNQRZQWRKDYH

DQ\ HIIHFW LQ FKRQGURVDUFRPD ZH DYHUDJHG  FKRQGURVDUFRPD FXOWXUHV

WRJHWDQLPSUHVVLRQRIWKHPRVWDFWLYHNLQDVHVDQGWKHSDWKZD\VWKH\DUH

involved in.

8VLQJ*,67ZHGHPRQVWUDWHGWKDWWKH3HSFKLS^®NLQRPHSURÀOLQJSODWIRUP

FRUUHFWO\LGHQWLÀHGWKHSDWKZD\VWKDWDUHNQRZQWRSOD\DQLPSRUWDQWUROH

LQ*,67DQGWKDWWKHLUDFWLYLW\LVGHFUHDVHGE\LPDWLQLEWUHDWPHQW8VLQJ

PHVHQFK\PDOVWHPFHOOVDQGDQLQGHSHQGHQWVHWRIFRORUHFWDOFDUFLQRPDFHOO

Figure 5.3 Decrease in cell vi- ability by dasatinib seems to be unrelated to inhibition of phos- phorylated Src and to caspase 3 mediated apoptosis in chondro- sarcoma. $ ZKLOH OHYHOV RI WRWDO

6UFGRQRWGHFUHDVHXSRQGDVDWLQLE

WUHDWPHQW LQ *,67 D GHFUHDVH

LQSKRVSKRU\ODWHG6UFS6UF< LVVKRZQXSRQGDVDWLQLEWUHDWPHQW

$WDGRVLVRIQ0GDVDWLQLEWKH

XSSHUEDQGRIWKHS6UFVWDLQLQJKDV

GLVDSSHDUHG DUURZ 6WDLQLQJ IRU

pro-caspase 3 shows a gradual de- FUHDVH LQ *,67 XSRQ GDVDWLQLE

WUHDWPHQW%LQ/WKHGDVDWLQLE

sensitive cell culture, levels of pSrc GHFUHDVH JUDGXDOO\ DOWKRXJK ERWK

EDQGVRIWKHVWDLQLQJDUHSUHVHQW$

decrease of pro-caspase 3 could not EHGHPRQVWUDWHGLQ/

&DOVRLQ&+WKHQRQUHVSRQ- sive cell culture, the level of phos- SKRU\ODWLRQ RI 6UF GHFUHDVHV XSRQ

GDVDWLQLE WUHDWPHQW $JDLQ QR GH- FUHDVH LQ SURFDVSDVH FRXOG EH

REVHUYHG

OLQHVZHDOVRGHPRQVWUDWHGWXPRXUVSHFLÀFLW\DQGWXPRXUW\SHVSHFLÀFLW\

UHVSHFWLYHO\

$QDO\VLQJ NLQRPH SURÀOHV RI  FKRQGURVDUFRPD FHOO FXOWXUHV LGHQWLÀHG

VHYHUDOGUXJDEOHWDUJHWV9DOLGDWLRQRIWKHUHVXOWVE\LPPXQREORWDVZHOO

DV WKH LQKLELWLRQ RI FKRQGURVDUFRPD FHOO YLDELOLW\ in vitro E\ GDVDWLQLE

GHPRQVWUDWHWKDWWKLVLVDQHOHJDQWDSSURDFKWRLGHQWLI\WDUJHWVIRUWUHDWPHQW

RIWXPRXUVIRUZKLFKVRIDUQRV\VWHPLFWUHDWPHQWRSWLRQVDUHDYDLODEOH

$QDO\VLQJ WKH WRS  DFWLYDWHG VXEVWUDWHV RI WKH  FKRQGURVDUFRPD

FHOO FXOWXUHV UHYHDOHG  DFWLYH NLQDVHV RI ZKLFK $.7 DQG *6.% ZHUH

VKRZQ WR EH WKH PRVW DFWLYH 7KH SKRVSKRU\ODWLRQ RI $.7 ZDV FRQÀUPHG

E\ LPPXQREORW 7KLV SDWKZD\ FDQ EH EORFNHG E\ (Q]DVWDXULQ D 3.&%

VHOHFWLYH LQKLELWRU WKDW KDV EHHQ VKRZQ WR VXSSUHVV DQJLRJHQHVLV DQG

LQGXFHV DSRSWRVLV LQ FRORUHFWDO FDQFHU DQG JOLREODVWRPD [HQRJUDIWV E\

WDUJHWLQJ $.7 DQG *6.%^ ,Q FRQWUDVW WR $.7 *6. LV FRQVWLWXWLYHO\

DFWLYH DQG EHFRPHV IXQFWLRQDOO\ LQDFWLYDWHG DIWHU SKRVSKRU\ODWLRQ *6.

KDVDFHQWUDOIXQFWLRQLQSK\VLRORJLFDOLHWUDQVFULSWLRQDSRSWRVLVDQGFHOO

F\FOH SURJUHVVLRQ DQG SDWKRORJLFDO LH GLDEHWHV PHOOLWXV $O]KHLPHU DQG

FDUFLQRJHQHVLVSURFHVVHVUHYLHZHGLQ²⁵,QFKRQGURVDUFRPDFHOOFXOWXUHV

ZHGHPRQVWUDWHGWKHDEVHQFHRISKRVSKRU\ODWLRQDWVHULQHLQGLFDWLYHIRU

DFWLYH *6.% $Q LPSRUWDQW UROH IRU WKH $.7 NLQDVH LQ FKRQGURVDUFRPD

VXUYLYDOZDVSUHYLRXVO\VXJJHVWHGE\-DQJHWDO^.

.LQRPHSURÀOLQJRIFKRQGURVDUFRPDDOVRUHYHDOHGDQDFWLYH6UFSDWKZD\6UF

SOD\VDUROHLQWKHUHJXODWLRQRIHPEU\RQLFGHYHORSPHQWDQGFHOOJURZWK^. 0XWDWLRQV LQ 6UF DUH LQYROYHG LQ WKH PDOLJQDQW SURJUHVVLRQ RI FRORUHFWDO

cancer²⁷:HLGHQWLÀHGDFWLYLW\RI)\QDQG/FNLQFKRQGURVDUFRPDZKLFK

DUH WRJHWKHU ZLWK <HV )JU +FN %ON /\Q DQG )UN PHPEHUV RI WKH 6UF

IDPLO\ 7KH 6UF SDWKZD\ FDQ EH WDUJHWHG E\ GDVDWLQLE 'DVDWLQLE LV ZHOO

NQRZQIRULWVHIÀFDF\LQWKHWUHDWPHQWRIFKURQLFP\HORJHQRXVOHXNHPLDDQG

3KLODGHOSKLDFKURPRVRPH²SRVLWLYH$//^LQZKLFKGDVDWLQLELQKLELWVWKH

$EONLQDVHV²⁹5HFHQWO\GDVDWLQLEKDVDOVREHHQVKRZQWREHHIIHFWLYHLQWKH

treatment of cells derived from solid tumours, i.e. prostate cancer³⁰ and head and neck squamous cell carcinoma^,QSUHYLRXVUHVHDUFKDOVRH[SUHVVLRQ

RI $EO NLQDVH ZDV VKRZQ LQ FKRQGURVDUFRPD E\ LPPXQRKLVWRFKHPLVWU\

ZLWKLQWHUHVWLQJO\DQHJDWLYHFRUUHODWLRQZLWKKLVWRORJLFDOJUDGH³². We show GHFUHDVHG FHOO YLDELOLW\ DIWHU GDVDWLQLE WUHDWPHQW LQ WKH PDMRULW\  RI

FKRQGURVDUFRPDFHOOFXOWXUHVDOWKRXJKDPD[LPXPRIRILQKLELWLRQRI

FHOOJURZWKZDVUHDFKHGZKLOHWKHHIIHFWLQ*,67DQGWKHOHXNHPLDFHOO

OLQHVZHUHPRUHSURIRXQG7KLVGLIIHUHQFHPD\EHH[SODLQHGE\VHFRQGDU\

events which stimulate cell growth in chondrosarcoma, ie. the loss of FHOO F\FOH LQKLELWLRQ ZKLFK ZDV SUHYLRXVO\ VKRZQ WR RFFXU LQ  RI WKH

tumours^/LNHZLVH*,67VKDYHEHHQVKRZQWREHFRPHUHIUDFWRU\WRLQLWLDO

VXFFHVVIXOUHVSRQVHWRLPDWLQLEGXHWRORVVRIFHOOF\FOHFRQWURO³³.



6WULNLQJO\ GRVH GHSHQGHQW LQKLELWLRQ RI 6UF NLQDVH SKRVSKRU\ODWLRQ E\

GDVDWLQLEDVPHDVXUHGE\DXWRSKRVSKRU\ODWLRQDW<ZDVIRXQGERWK

LQDUHVSRQVLYH/DQGLQDQRQUHVSRQVLYH&+FHOOFXOWXUH7KLV

VXJJHVWVWKDWJURZWKLQKLELWLRQLQGXFHGE\GDVDWLQLEPLJKWEHLQGHSHQGHQW

RI 6UF NLQDVH SKRVSKRU\ODWLRQ 7KXV GDVDWLQLE PLJKW H[HUW LWV IXQFWLRQ

YLD RWKHU SDWKZD\V LQ FKRQGURVDUFRPD LH E\ LQKLELWLRQ RI $EO NLQDVHV

ÀEUREODVW JURZWK IDFWRU UHFHSWRU NLQDVHV RU 3'*) UHFHSWRU NLQDVHV^ or

$.7³⁵$FWLYLW\RIWKHODWWHUWZRLVGHPRQVWUDWHGLQWKHSUHVHQWVWXG\

:KLOHGDVDWLQLEZDVVXJJHVWHGWRLQGXFHFDVSDVHPHGLDWHGDSRSWRVLVLQ

WKHFRQWURO*,67FHOOOLQHWKLVZDVQRWREVHUYHGLQFKRQGURVDUFRPDFHOO

FXOWXUHV7KLVVXJJHVWVWKDWGDVDWLQLELQKLELWVFKRQGURVDUFRPDFHOOJURZWK

WKURXJKRWKHUPHFKDQLVPVIRUH[DPSOHE\LQGXFLQJ*DUUHVW+RZHYHU

LPPXQREORWWLQJIRUS6UFDQGFDVSDVHZDVSHUIRUPHGRQRQHUHVSRQVLYH

DQGRQHQRQUHVSRQVLYHFHOOOLQHRQO\DQGH[WUDSRODWLQJWKHVHUHVXOWVWRDOO

FKRQGURVDUFRPDVVKRXOGEHGRQHZLWKFDXWLRQ

0RUHH[SHULPHQWVDUHQHHGHGWRIXUWKHUH[SORUHWKHPHFKDQLVPXQGHUO\LQJ

JURZWKLQKLELWLRQDQGZKHWKHUWKHHIIHFWVRIGDVDWLQLERQFKRQGURVDUFRPD

JURZWKFDQEHLQFUHDVHGE\FRPELQDWLRQZLWKDQRWKHUF\WRVWDWLFFRPSRXQG

WRUHDFKKLJKHUJURZWKLQKLELWLRQUDWHV

'HVSLWHWKHÀQGLQJRI3'*)5%DFWLYLW\XVLQJWKH3HSFKLS^® and the fact that 3'*)5$SURWHLQH[SUHVVLRQ^DQGDFWLYLW\RIWKHDOSKDDQGEHWDUHFHSWRUZHUH

UHSRUWHGSUHYLRXVO\LQWKHDEVHQFHRIJDLQRIIXQFWLRQPXWDWLRQV^, we were QRWDEOHWRGHFUHDVHFHOOYLDELOLW\RIFKRQGURVDUFRPDFHOOFXOWXUHVE\LPDWLQLE

WUHDWPHQW,QFRQWUDVW.OHQNHet alVKRZHG68ZKLFKLQKLELWVW\URVLQH

NLQDVHV 3'*)5% )ON.'5 DQG )*)5 WR UHSUHVV FKRQGURVDUFRPD

growth via antiangiogenesis in vivo^. One must take into account that we VWXGLHGWKHHIIHFWRIGDVDWLQLEDQGLPDWLQLELQFKRQGURVDUFRPDin vitro, and that an additional effect in vivoWKURXJKWKHLQKLELWLRQRIDQJLRJHQHVLVPD\

EHSRVVLEOHDVKDVEHHQGHVFULEHGIRUGDVDWLQLE³⁷.

$OVR )ODYRSLULGRO DQG $=' LQKLELWRUV RI &'& DQG $XURUD NLQDVH

DFWLYLW\UHVSHFWLYHO\ZHUHVXJJHVWHGIRUFKRQGURVDUFRPDWUHDWPHQWE\RXU

Pepchip^®DSSURDFK7DEOH)ODYRSLULGROLVDSDQF\FOLQGHSHQGHQWNLQDVH

LQKLELWRUQRWRQO\WDUJHWLQJ&'&DOVRNQRZQDVF\FOLQGHSHQGHQWNLQDVH

 EXW DOVR F\FOLQ GHSHQGHQW NLQDVH  DQG  3UHYLRXVO\ ZH UHSRUWHG WKH

DPSOLÀFDWLRQRIT⁹WKHORFXVRI&'.LQFUHDVHGH[SUHVVLRQRI&'.

DQGDGHFUHDVHLQFHOOYLDELOLW\XVLQJVK51$WRNQRFNGRZQ&'.H[SUHVVLRQ

in vitro^ :H VXJJHVWHG WKH XVH RI &'. LQKLELWRUV LQ WKH WUHDWPHQW RI

FKRQGURVDUFRPDZKLFKLVQRZEHLQJHPSKDVLVHGDFFRUGLQJO\LQWKHSUHVHQW

VWXG\$OVR536NLQDVHZDVIRXQGWREHDFWLYHLQFKRQGURVDUFRPDZKLFK

ZDVIRXQGWRSUHGLFWWKHUHVSRQVHWRP725LQKLELWRUVLQVDUFRPD^536

NLQDVH LV UHVSRQVLEOH IRU WKH SKRVSKRU\ODWLRQ RI ULERVRPDO SURWHLQ 6

ZKLFKZHSUHYLRXVO\IRXQGWREHGHOHWHGDQGGRZQUHJXODWHGLQDVXEVHWRI

chondrosarcomas⁹7KLVVXJJHVWVWKDWWKHWXPRXUFHOOVPD\WU\WRRYHUFRPH

WKLVGHOHWLRQE\SKRVSKRU\ODWLRQ1RDUUD\&*+GDWDZHUHDYDLODEOHIRUWKH

FHOOFXOWXUHVGHVFULEHGKHUH

,QWKHSUHVHQWVWXG\ZHUHSRUWWKHNLQRPHSURÀOLQJRIFKRQGURVDUFRPD

FHOOFXOWXUHVDQGE\DYHUDJLQJWKHSURÀOHVZHLGHQWLÀHGDFWLYLW\RIWKH6UF

SDWKZD\ $FFRUGLQJO\ 6UF LQKLELWRU GDVDWLQLE GHFUHDVHG FHOO YLDELOLW\ LQ

VHYHQRXWRIQLQHFKRQGURVDUFRPDFHOOFXOWXUHV2XUH[SHULPHQWVVXJJHVW

WKDWGDVDWLQLELVDSRWHQWLDOWUHDWPHQWRSWLRQLQFKRQGURVDUFRPDWUHDWPHQW

Future studies in vivoVKRXOGEHSHUIRUPHGWRFRQÀUPWKHVHGDWDDQGWR

LQYHVWLJDWHWKHFRPELQDWLRQZLWKFRQYHQWLRQDOFKHPRWKHUDS\DQGSRVVLEOH

DGGLWLRQDOHIIHFWVWKURXJKWKHLQKLELWLRQRIDQJLRJHQHVLV

Acknowledgements

7KH DXWKRUV OLNH WR WKDQN - 2RVWLQJ IRU KHOS ZLWK GDWD DQDO\VLV DQG +

+DXJH IURP %LRPROH[ $6 2VOR DQG 5 2IIULQJD IURP /HLGHQ 8QLYHUVLW\

,QVWLWXWH RI %LRORJ\ IRU WKH XVH RI WKH %LRPROH[ UHDGHU -- %DHOGH &

*DOYDQ$PSXGLD3.RHOLQN'0HLMHUDQG&0$5HLMQGHUVDUHWKDQNHG

IRU H[SHUW WHFKQLFDO DVVLVWDQFH - -RRUH 3HSVFDQ 3UHVWR %9 /HO\VWDG

+ROODQG $- *HOGHUEORP DQG $0 &OHWRQ-DQVHQ DUH DFNQRZOHGJHG IRU

IUXLWIXOGLVFXVVLRQV-$)OHWFKHU%ULJKDP :RPHQ·V+RVSLWDO%RVWRQ

86$  7 .DOLQVNL 2WWRYRQ*XHULFNH8QLYHUVLW\ 0DJGHEXUJ *HUPDQ\

% 1LMPHLMHU /80& /HLGHQ 7KH 1HWKHUODQGV HQ 0 1DPED 2ND\DPD

8QLYHUVLW\0HGLFDO6FKRRO6KLNDWD-DSDQDUHWKDQNHGIRUSURYLGLQJFHOO

OLQHV*,67&$//&0 &5DQG2806UHVSHFWLYHO\

Reference List

  (ULNVVRQ$,6FKLOOHU$0DQNLQ+-7KHPDQDJHPHQWRIFKRQGURVDUFRPDRI

ERQHClin Orthop

  %RYpH-90*&OHWRQ-DQVHQ$07DPLQLDX$+0+RJHQGRRUQ3&:(PHUJLQJ

SDWKZD\VLQWKHGHYHORSPHQWRIFKRQGURVDUFRPDRIERQHDQGLPSOLFDWLRQVIRU

targeted treatment. Lancet Oncology

  *HOGHUEORP + +RJHQGRRUQ 3&: 'LMNVWUD 6' YDQ 5LMVZLMN &6 .URO $'

7DPLQLDX$+HWDO7KHFOLQLFDODSSURDFKWRZDUGVFKRQGURVDUFRPDOncologist



  9HWK56FKUHXGHU%YDQ%HHP+3UXV]F]\QVNL0GH5RR\-&U\RVXUJHU\

LQDJJUHVVLYHEHQLJQDQGORZJUDGHPDOLJQDQWERQHWXPRXUVLancet Oncol



  (YDQV+/$\DOD$*5RPVGDKO003URJQRVWLFIDFWRUVLQFKRQGURVDUFRPD

RI ERQH $ FOLQLFRSDWKRORJLF DQDO\VLV ZLWK HPSKDVLV RQ KLVWRORJLF JUDGLQJ

Cancer

  5HOLDELOLW\ RI +LVWRSDWKRORJLF DQG 5DGLRORJLF *UDGLQJ RI &DUWLODJLQRXV

Neoplasms in Long Bones. J Bone Joint Surg Am$

  (HIWLQJ'6FKUDJH<0*HLUQDHUGW0-/H&67DPLQLDX$+0%RYpH-90*

HW DO $VVHVVPHQW RI LQWHUREVHUYHU YDULDELOLW\ DQG KLVWRORJLF SDUDPHWHUV

WR LPSURYH UHOLDELOLW\ LQ FODVVLÀFDWLRQ DQG JUDGLQJ RI FHQWUDO FDUWLODJLQRXV



  %MRUQVVRQ - 0F/HRG 5$ 8QQL .. ,OVWUXS '0 3ULWFKDUG '- 3ULPDU\

FKRQGURVDUFRPDRIORQJERQHVDQGOLPEJLUGOHVCancer

  5R]HPDQ/%6]XKDL.6FKUDJH<05RVHQEHUJ&7DQNH+-7DPLQLDX$+0

HW DO $UUD\FRPSDUDWLYH JHQRPLF K\EULGL]DWLRQ RI FHQWUDO FKRQGURVDUFRPD

 ,GHQWLÀFDWLRQ RI ULERVRPDO SURWHLQ 6 DQG F\FOLQGHSHQGHQW NLQDVH  DV

FDQGLGDWHWDUJHWJHQHVIRUJHQRPLFDEHUUDWLRQVCancer

 6FKUDJH <0 /DP 6 -RFKHPVHQ $* &OHWRQ-DQVHQ $0 7DPLQLDX $+

+RJHQGRRUQ 3& HW DO &HQWUDO FKRQGURVDUFRPD SURJUHVVLRQ LV DVVRFLDWHG

ZLWKS5ESDWKZD\DOWHUDWLRQV&'.GRZQUHJXODWLRQDQGSRYHUH[SUHVVLRQ

LQKLELWFHOOJURZWKLQYLWURJ Cell Mol Med in press.

 $VS - 6DQJLRUJL / ,QHURW 6( /LQGDKO $ 0ROHQGLQL / %HQDVVL 06 HW DO

&KDQJHV RI WKH S JHQH EXW QRW WKH S JHQH LQ KXPDQ FKRQGURVDUFRPD

tissues. Int J Cancer

 YDQ %HHUHQGRQN +0 5R]HPDQ /% 7DPLQLDX $+0 6FLRW 5 %RYpH -90*

&OHWRQ-DQVHQ$0HWDO0ROHFXODUDQDO\VLVRIWKH,1.$,1.$$5)JHQH

ORFXVLQFRQYHQWLRQDOFHQWUDOFKRQGURVDUFRPDVDQGHQFKRQGURPDVLQGLFDWLRQ

of an important gene for tumour progression. J Pathol

 -DQJ-+&KXQJ&37HQDVFLQ&SURPRWHVFHOOVXUYLYDOE\DFWLYDWLRQRI$NWLQ

human chondrosarcoma cell. Cancer Lett

 /DJRQLJUR067DPERULQL(1HJUL76WDXUHQJR6'DJUDGD*30LVHOOL)HW

DO3'*)5DOSKD3'*)5EHWDDQG.,7H[SUHVVLRQDFWLYDWLRQLQFRQYHQWLRQDO

chondrosarcoma. J Pathol

 .OHQNH )0 $EGROODKL $ %HUWO ( *HEKDUG 00 (ZHUEHFN 9 +XEHU 3( HW

DO7\URVLQHNLQDVHLQKLELWRU68UHSUHVVHVFKRQGURVDUFRPDJURZWKYLD

antiangiogenesis in vivo. Bmc Cancer 2007;7.

 -RKQVRQ6$+XQWHU7.LQRPLFVPHWKRGVIRUGHFLSKHULQJWKHNLQRPHNat Methods

 'LNV6+.RN.2·7RROH7+RPPHV':YDQ'LMNHQ3-RRUH-HWDO.LQRPH

SURÀOLQJ IRU VWXG\LQJ OLSRSRO\VDFFKDULGH VLJQDO WUDQVGXFWLRQ LQ KXPDQ

SHULSKHUDOEORRGPRQRQXFOHDUFHOOVJ Biol Chem

 7XYHVRQ '$ :LOOLV 1$ -DFNV 7 *ULIÀQ -' 6LQJHU 6 )OHWFKHU &' HW DO

67,LQDFWLYDWLRQRIWKHJDVWURLQWHVWLQDOVWURPDOWXPRXUF.,7RQFRSURWHLQ

ELRORJLFDODQGFOLQLFDOLPSOLFDWLRQVOncogene

 &OHWRQ-DQVHQ$0YDQ%HHUHQGRQN+0%DHOGH+-%RYpH-90*.DUSHULHQ

0+RJHQGRRUQ3&:(VWURJHQVLJQDOOLQJLVDFWLYHLQFDUWLODJLQRXVWXPRXUV

LPSOLFDWLRQVIRUDQWLHVWURJHQWKHUDS\DVWUHDWPHQWRSWLRQRIPHWDVWDVL]HGRU

LUUHVHFWDEOHFKRQGURVDUFRPDClin Cancer Res

 :HWWHQKDOO -0 6P\WK *. OLPPD*8, D JUDSKLFDO XVHU LQWHUIDFH IRU OLQHDU

PRGHOLQJRIPLFURDUUD\GDWDBioinformatics

 6FKUDJH <0 +DPHHWPDQ / 6]XKDL . &OHWRQ-DQVHQ $0 7DPLQLDX $+

+RJHQGRRUQ 3& HW DO $EHUUDQW KHSDUDQ VXOIDWH SURWHRJO\FDQ ORFDOL]DWLRQ

GHVSLWH QRUPDO H[RVWRVLQ LQ FHQWUDO FKRQGURVDUFRPD Am J Pathol



 6FKLWWHQKHOP006KLUDJD66FKURHGHU$&RUELQ$6*ULIÀWK'/HH)<HW

DO'DVDWLQLE%06DGXDO65&$%/NLQDVHLQKLELWRULQKLELWVWKH

NLQDVHDFWLYLW\RIZLOGW\SHMX[WDPHPEUDQHDQGDFWLYDWLRQORRSPXWDQW.,7

isoforms associated with human malignancies. Cancer Res

 5LFKWHU0:HLVV0:HLQEHUJHU,)XUVWHQEHUJHU*0DULDQ%*URZWKLQKLELWLRQ

DQG LQGXFWLRQ RI DSRSWRVLV LQ FRORUHFWDO WXPRXU FHOOV E\ F\FORR[\JHQDVH

LQKLELWRUVCarcinogenesis

 *UDII-50F1XOW\$0+DQQD.5.RQLFHN%:/\QFK5/%DLOH\61HWDO

7KH SURWHLQ NLQDVH &EHWDVHOHFWLYH LQKLELWRU (Q]DVWDXULQ /<+&O

VXSSUHVVHV VLJQDOOLQJ WKURXJK WKH $.7 SDWKZD\ LQGXFHV DSRSWRVLV DQG

VXSSUHVVHV JURZWK RI KXPDQ FRORQ FDQFHU DQG JOLREODVWRPD [HQRJUDIWV

Cancer Res

 &RKHQ3)UDPH67KHUHQDLVVDQFHRI*6.Nat Rev Mol Cell Biol

 5XGG&(7UHYLOO\DQ-0'DVJXSWD-':RQJ//6FKORVVPDQ6)7KH&'

UHFHSWRULVFRPSOH[HGLQGHWHUJHQWO\VDWHVWRDSURWHLQW\URVLQHNLQDVHSS IURPKXPDQ7O\PSKRF\WHVProc Natl Acad Sci U S A

 ,UE\5%0DR:&RSSROD'.DQJ-/RXEHDX-07UXGHDX:HWDO$FWLYDWLQJ

65& PXWDWLRQ LQ D VXEVHW RI DGYDQFHG KXPDQ FRORQ FDQFHUV Nat Genet



 7DOSD] 0 6KDK 13 .DQWDUMLDQ + 'RQDWR 1 1LFROO - 3DTXHWWH 5 HW DO

'DVDWLQLELQLPDWLQLEUHVLVWDQW3KLODGHOSKLDFKURPRVRPHSRVLWLYHOHXNHPLDV

N Engl J Med

 6KDK137UDQ&/HH)<&KHQ31RUULV'6DZ\HUV&/2YHUULGLQJLPDWLQLE

UHVLVWDQFHZLWKDQRYHO$%/NLQDVHLQKLELWRUScience

 1DP6.LP'&KHQJ-4=KDQJ6/HH-+%XHWWQHU5HWDO$FWLRQRIWKH6UF

IDPLO\NLQDVHLQKLELWRUGDVDWLQLE%06RQKXPDQSURVWDWHFDQFHU

cells. Cancer Res

 -RKQVRQ )0 6DLJDO % 7DOSD] 0 'RQDWR 1- 'DVDWLQLE %06 W\URVLQH NLQDVH LQKLELWRU VXSSUHVVHV LQYDVLRQ DQG LQGXFHV FHOO F\FOH DUUHVW

and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res

 2·'RQRYDQ 0 5XVVHOO -0 2·/HDU\ -- *LOODQ -$ /DZOHU 03 *DIIQH\ ()

$EOH[SUHVVLRQWXPRXUJUDGHDQGDSRSWRVLVLQFKRQGURVDUFRPDMol Pathol



 5RPHR6'LHELHF5\FKWHU09DQ*ODEEHNH0YDQ3DDVVHQ+&RPLWH3YDQ

(LMN5HWDO&HOOF\FOHDSRSWRVLVPROHFXOHVH[SUHVVLRQFRUUHODWHVZLWK,PDWLQLE

response in patients with advanced Gastro-Intestinal Stromal Tumours. Clin Cancer Res

 /RPEDUGR/-/HH)<&KHQ31RUULV'%DUULVK-&%HKQLD.HWDO'LVFRYHU\

RI 1FKORURPHWK\O SKHQ\OK\GUR[\HWK\O SLSHUD]LQ\O

PHWK\OS\ULPLGLQ \ODPLQRWKLD]ROHFDUER[DPLGH %06 D GXDO

6UF$EONLQDVHLQKLELWRUZLWKSRWHQWDQWLWXPRXUDFWLYLW\LQSUHFOLQLFDODVVD\V

J Med Chem

 9HOGXUWK\$3DW]0+DJLVW63DOODVFK&3:HQGWQHU&0+DOOHN0HWDO7KH

NLQDVHLQKLELWRUGDVDWLQLELQGXFHVDSRSWRVLVLQFKURQLFO\PSKRF\WLFOHXNHPLD

FHOOVLQYLWURZLWKSUHIHUHQFHIRUDVXEJURXSRISDWLHQWVZLWKXQPXWDWHG,J9+

genes. Blood

 6XO]EDFKHU,%LUQHU37ULHE.0XKOEDXHU0/DQJ6&KRWW$3ODWHOHWGHULYHG

JURZWKIDFWRUDOSKDUHFHSWRUH[SUHVVLRQVXSSRUWVWKHJURZWKRIFRQYHQWLRQDO

chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol



 &ROXFFLD $0 &LUXOOL 7 1HUL 3 0DQJLHUL ' &RODQDUGL 0& *QRQL $ HW DO

9DOLGDWLRQRI3'*)5EHWDDQGF6UFW\URVLQHNLQDVHVDVWXPRXUYHVVHOWDUJHWV

LQ SDWLHQWV ZLWK PXOWLSOH P\HORPD SUHFOLQLFDO HIÀFDF\ RI WKH QRYHO RUDOO\

DYDLODEOHLQKLELWRUGDVDWLQLEBlood

 ,ZHQRIX2+/DFNPDQ5'6WDGGRQ$3*RRGZLQ'*+DXSW+0%URRNV-6

3KRVSKR6ULERVRPDOSURWHLQDSRWHQWLDOQHZSUHGLFWLYHVDUFRPDPDUNHUIRU

WDUJHWHGP725WKHUDS\Mod Pathol

 .XQLVDGD70L\D]DNL00LKDUD.*DR&.DZDL$,QRXH+HWDO$QHZ

KXPDQ FKRQGURVDUFRPD FHOO OLQH 2806 WKDW PDLQWDLQV FKRQGURF\WLF



differentiation. Int J Cancer

 *LO%HQVR 5 /RSH]*LQHV & /RSH]*XHUUHUR -$ &DUGD & &DOODJKDQ 5&

1DYDUUR6HWDO(VWDEOLVKPHQWDQGFKDUDFWHUL]DWLRQRIDFRQWLQXRXVKXPDQ

FKRQGURVDUFRPDFHOOOLQHFKFRPSDUDWLYHKLVWRORJLFDQGJHQHWLFVWXGLHV

with its tumour of origin. Lab Invest

 .DOLQVNL 7 .UXHJHU 6 3HO] $) :LHDFNHU 3 +DUWLJ 5 5RSNH 0 HW DO

(VWDEOLVKPHQWDQGFKDUDFWHUL]DWLRQRIWKHSHUPDQHQWKXPDQFHOOOLQH&

GHULYHGIURPDVHFRQGDU\FKRQGURVDUFRPDLQ2OOLHU·VGLVHDVHVirchows Arch



Average intensity in

CS cultures Substrate Protein Psite Corresponding

kinase Change

MSC (log2)

Adj p-value MSC

 5...9667.5+ &\WRKHVLQ 6 3.&  

 5.*<5645*+6 Vitronectin 6 3.&  

709.03 5$5676/1(53 7XEHULQ S939 $.7  

 633566/5566 Transcription elongation factor

$OLNH S37 3.&*6.  

 /556/656064 Telethonin 6 Titin 0.77 

 043'166'6'< CD5 7 3.$ -0.35 

 **5**65$51/ +HWHURJHQHRXVQXFOHDU

ULERQXFOHRSURWHLQ. S302 3.&GHOWD  

 /.3*66+5.7. %UXWRQ·VW\URVLQHNLQDVH 6 3.&EHWD  

 5550$60457* ($ELQGLQJSURWHLQS 6 $.7S6

NLQDVHSS5VN 0.53 

 +/56(645455 *XDQLQHQXFOHRWLGHELQGLQJ

SURWHLQDOSKD=SRO\SHSWLGH S27 3.&  

 5351<69*653 SKRVSKRIUXFWRNLQDVH

IUXFWRVHELSKRVSKDWDVH 6 $.7  0.003

 ...,$75.35) 0HWDERWURSLFJOXWDPDWH

UHFHSWRU 7 3.&  

 '166'6'<'/+ CD5 7 /FN)\Q -2.09 

377.39 /54/56355$4 5DVDVVRFLDWHGSURWHLQ5DE 6 CDC2  

 6645966<557 Desmin 6 Aurora kinase B  0.255

 $5,**655(56 (3UHFHSWRU 6 3.& 0.29 

 (3.556$5/6$ +0* S7 536NLQDVH

DOSKD3.$

3.&  

 65.*<65.*)' 3HSWLG\OJO\FLQHDOSKD

DPLGDWLQJPRQRR[\JHQDVH S930 3.&  

 555/66/5$67 5LERVRPDOSURWHLQ6 6 3$. 0.02 

 5613365.*6* &RQQH[LQ S233 3.&3.$  

 $$.5$65,<17 5HJXODWRURI*SURWHLQ

VLJQDOOLQJ 6 3.$ 0.50 

 /555/6'66), 6\QDSVLQ,, 6 3.$ 0.33 

 5*5*669***6 $6. 6 $.7  

 5755,647649 5\DQRGLQHUHFHSWRU 6 3.$  0.000

 5.5.3676''6 DNA topoisomerase II aplha 6 &.  

 5355566$96/ &\FOLF*03LQKLEHG

phosphodiesterase B S295 $.7  

 7('4<6/9('' 3KRVSKDWLG\OLQRVLWRONLQDVH

UHJXODWRU\VXEXQLWDOSKD 6

Phospho- inositide-3- NLQDVHFDWDO\WLF

VXEXQLWJDPPD

 0.092

 $3.$36..(.. DAB2 6 3.&  0.003

 335566,51$+ SSKR[ 6

3.&]HWD

3.&DOSKD

3.&EHWD,,

3.&GHOWD

 

 ,.54/607/5* 3&7$,5(SURWHLQNLQDVH 6 3.$  0.000

300.32 673$3657$6) $73FLWUDWHO\DVH 6 *6. 0.55 

 5(5.66$36+6 GAB2 6 $.7  0.009

293.33 156)/6/.+73 Notch2 nd 3.03 0.000

 5.55:6$3(65 $WD[LQ 6 $7.  0.000

 6'65.605467 7&)/ 6 3.&  

 /555/6'61)0 6\QDSVLQ, S9 &D0.,3.$  0.737



 $95/56693*9 5KRNLQDVH 

272.05 3733/636556 F0\F 7 &.*6.  

270.99 965676)5**0 .HUDWLQ S52 &$0.536

kinase alpha 3;

3.&HSVLORQ  

 .3.'$645556 c-Src 6 3.&  

 */5566.)$/. Beta-2-adrenergic receptor 6 3.&  0.007

 6.5516()(,) 7U\SWRSKDQK\GUR[\ODVH 6 35.$  0.000

 :55.66'5.** +/$$ S337

Protein NLQDVHF$03

dependent, UHJXODWRU\W\SH,

DOSKD

 

 /75,36$..<. 3($ 6 3.& 0.75 

 *(.5$663)55 Nucleolar phosphoprotein

S 6 3.$ 0.33 

 /65536<5.,/ F$03UHVSRQVHHOHPHQW

ELQGLQJSURWHLQ 6 3.$0$3.

&D0.56. -0.22 

 *355565.3($ Centromeric protein a S7 Aurora kinase B  0.009

 555$$60'666 $); 6 $.7  0.002

250.33 055456$3'/. .LQHVLQIDPLO\PHPEHU& 6 &.  

 .,55/6$$.44 /.% 6 S56.06.

6.3.$/.%  

 55.$$705(55 0\RJHQLFGLIIHUHQWLDWLRQ

DQWLJHQ 7 3.& 0.59 

 3656<6(5')( 6ROXWHFDUULHUIDPLO\DQLRQ

H[FKDQJHPHPEHU 6 3.&HSVLORQ  0.209

 6950/6*6.(. Opioid receptor mu 6 &$0.,,  

 *4/5*6$75$/ &DVHLQNLQDVHHSVLORQ S323 &.HSVLORQ  

 5456767319+ 5$) S259 3.$$.7 -0.35 0.553

 9$$5$7/5561 Calcium sensing receptor 7 3.& 3.77 0.000

235.20 <5(50661531 0HSULQEHWDVXEXQLW 6 3.&  0.003

235.05 ..*$5655/)6 *XDQLQHQXFOHRWLGHELQGLQJ

SURWHLQDOSKDVXEXQLW 6 3.&DOSKD  0.000

 //6(/6555,5 eIF2 alpha S52  

229.53 *.15366*6/, 4XLQRLGGLK\GURSWHULGLQH

reductase S223 &$0.,,  

 96('16('(,6 $FHW\O&R$FDUER[\ODVHDOSKD 66 &.  

 /$5537.*,+( *XDQLQHQXFOHRWLGHELQGLQJ

SURWHLQDOSKD T203 3.$  0.059

 5'5666$319+ %5DI 6 $.76*.  

 7:55*67$**$ &DOSDLQODUJHSRO\SHSWLGH/ 7 nd  

 5.*+(<71,.< 6+3 < 3'*)5EHWD  0.020

 $6933636/65 *O\FRJHQV\QWKDVH 6 *6.EHWD  

 /6*5*61<*6/ 135$ 6 nd  

 ,93*.6375.. 5$3*73DVHDFWLYDWLQJ

SURWHLQ 6 CDC2 0.97 0.092

220.52 5.5.16597)6 1,33 6 3.$  

 5$5(*6)(65< 3KRVSKROLSDVH&JDPPD 6 3.&PX  

 5656563535* (UE% 6 Phospholipid

kinase; Phospho- inositide kinase

-0.05 0.950

 65.5/64'$<5 SSKR[ S320 3.&DOSKD

3.&EHWD,,

3.&GHOWD  0.003

 936<'6)'6(' &HWVSURWHLQ 6 &D0.  0.029

 //5($6$5'54 9DQLOORLGUHFHSWRU 6 3.&HSVLORQ  0.003

 $/95*7395*$ 6DP 7 CDC2  0.000

 9/$436765.5 &+. 6 3.$3.*  

 //56*6631/1 ($ELQGLQJSURWHLQS 6 3.&GHOWD  0.009

 $3'(*6'/)<' &HOOGLYLVLRQF\FOH S203 &. -2.00 

203.93 ,$95.65'.$. &&$$7(QKDQFHUELQGLQJ

SURWHLQEHWD T235 (5.  

 *$5566:59,6 (WD 66 6'. -0.55 

 53'366)6535 Opioid receptor 6 3.& 0.02 

 ($.5.63...( Coilin 6 &'.F\FOLQ( -0.09 

 5'5+/6)6*6* &' 6 3.&  0.059

 3665$665$66 &RQQH[LQ 6 nd  

 4/5536'5(/6 1).% 6 3.$ 0.33 

 1655365$0:/ Vitronectin S397 3.$ 0.97 

 ....365/.*' APC 6 3.$ -0.57 

 9+5'/65'53/ .HOOEORRGJURXSSURWHLQ 6 3.& 2.02 0.000

 $/55(64*6/1 5HJXODWRURI*SURWHLQ

VLJQDOOLQJ 6 3.$  

 +6/3/63$675 1).% S907 *6.EHWD 0.59 

 *)75.695.$4 Protein phosphatase 2,

UHJXODWRU\VXEXQLW%DOSKD 6 3.5  0.302

 */<656*6/6* 3.1 6 3.1 -0.03 

 /45666).')$ 6+SURWHLQH[SUHVVHGLQ

O\SKRF\WHV S27 nd 0.00